Preliminary progress report of a clinical study of the effect of C.V.P. on gingival hemorrhage

Abstract

Summaryo1.Twenty-five patients were divided into three groups: (A) nine patients received six C.V.P. capsules daily, (B) eight patients received six placebo capsules daily, and (C) eight patients received no capsules and acted as controls. All patients were examined biweekly for at least three months.2.Salutary response was noted in eight out of nine patients receiving six capsules of C.V.P. daily in that the bleeding tendency was diminished. This was in contrast to five out of eight patients receiving six placebo capsules daily who showed no improvement, as well as five out of eight patients in the control group who showed no improvement.3.The results noted in this experiment in no way imply that a lack of ascorbic acid and/or bioflavonoids is the only factor involved in hemorrhagic gingivitis. There is a need for a more objective clinical evaluation, other than those criteria used in this preliminary experiment. There is also a need for testing a larger group with a more equable distribution as to age and sex.4.The results of this study indicate that the use of ascorbic acid with bioflavonoids may be of some supportive value in cases of gingival hemorrhage. Scaling, curettage, oral physiotherapy, occlusal equilibration, and the removal of any or all known local as well as systemic factors which may be implicated must not be overlooked in order to successfully conclude and prevent early recurrence of periodontal disease of which gingival hemorrhage may be only one of the clinical symptoms. Twenty-five patients were divided into three groups: (A) nine patients received six C.V.P. capsules daily, (B) eight patients received six placebo capsules daily, and (C) eight patients received no capsules and acted as controls. All patients were examined biweekly for at least three months. Salutary response was noted in eight out of nine patients receiving six capsules of C.V.P. daily in that the bleeding tendency was diminished. This was in contrast to five out of eight patients receiving six placebo capsules daily who showed no improvement, as well as five out of eight patients in the control group who showed no improvement. The results noted in this experiment in no way imply that a lack of ascorbic acid and/or bioflavonoids is the only factor involved in hemorrhagic gingivitis. There is a need for a more objective clinical evaluation, other than those criteria used in this preliminary experiment. There is also a need for testing a larger group with a more equable distribution as to age and sex. The results of this study indicate that the use of ascorbic acid with bioflavonoids may be of some supportive value in cases of gingival hemorrhage. Scaling, curettage, oral physiotherapy, occlusal equilibration, and the removal of any or all known local as well as systemic factors which may be implicated must not be overlooked in order to successfully conclude and prevent early recurrence of periodontal disease of which gingival hemorrhage may be only one of the clinical symptoms.